scholarly journals Effect of modulation on immunocytes` activity of oncologic patients by biogenic metals` nanoparticles

2016 ◽  
Vol 11 (1) ◽  
Author(s):  
Elena Zlatnik ◽  
Galina Zakora ◽  
Evgeniya Nepomnyaschaya
Keyword(s):  
Oncologic Patients ◽  
Biogenic Metals

MicroRNAs and their role in hematological malignant diseases

2012 ◽  
Vol 153 (52) ◽  
pp. 2051-2059 ◽  
Author(s):  
Zsuzsanna Gaál ◽  
Éva Oláh
Keyword(s):  
Target Genes ◽  
Lymphoblastic Leukemia ◽  
Cancer Tissue ◽  
Altered Expression ◽  
Diagnosis And Prognosis ◽  
Oncologic Patients ◽  
Different Types ◽  
Non Coding Rnas ◽  
Success Of Treatment ◽  
Posttranscriptional Level

MicroRNAs are a class of small non-coding RNAs regulating gene expression at posttranscriptional level. Their target genes include numerous regulators of cell cycle, cell proliferation as well as apoptosis. Therefore, they are implicated in the initiation and progression of cancer, tissue invasion and metastasis formation as well. MicroRNA profiles supply much information about both the origin and the differentiation state of tumours. MicroRNAs also have a key role during haemopoiesis. An altered expression level of those have often been observed in different types of leukemia. There are successful attempts to apply microRNAs in the diagnosis and prognosis of acute lymphoblastic leukemia and acute myeloid leukemia. Measurement of the expression levels may help to predict the success of treatment with different kinds of chemotherapeutic drugs. MicroRNAs are also regarded as promising therapeutic targets, and can contribute to a more personalized therapeutic approach in haemato-oncologic patients. Orv. Hetil., 2012, 153, 2051–2059.

Pain Biomarkers in Cancer: An Overview

2020 ◽  
Vol 26 ◽  
Author(s):  
Fabrizio Calapai ◽  
Epifanio Mondello ◽  
Carmen Mannucci ◽  
Emanuela Elisa Sorbara ◽  
Sebastiano Gangemi ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Bone Cancer ◽  
Common Symptom ◽  
Scientific Databases ◽  
Reactive Protein ◽  
Cancer Breast ◽  
Oncologic Patients ◽  
Few Data ◽  
Analgesic Response ◽  
Pro Inflammatory Cytokines

Background: Pain is a common symptom in oncologic patients and its management is generally guided by pain individually perceived by patients and expressed through self-reported scales. However, the utility of these tools is limited because strongly dependent on patients’ opinions. For this reason, more objective instruments are desirable. Objective: In this overview scientific articles indicating potential markers to be used for pain management in cancer were collected and discussed. Methods: research was performed on principal electronic scientific databases by using the words “pain”, “cancer”, “markers” as “biomarkers” as the main keywords, and findings describing potential biomarkers for the management of cancer pain were reported. Results: Studies on pain markers not specific for cancer typology (inflammatory, genetic, markers predicting response to analgesic drugs, neuroimaging markers) and pain markers for specific types of cancer (bone cancer, breast cancer, lung cancer, head and neck cancer, prostate cancer, cancer in pediatrics) are presented and commented. Conclusion: This overview supports the view of the involvement of inflammatory mediators in the mechanisms underlying cancer pain. Up today only a few data from research on markers can help in the management of pain, except for pro-inflammatory cytokines and other inflammatory indexes such as C-reactive protein (CRP). However, biomarkers are a promising strategy useful to predict pain intensity and to purchase objective quantification of analgesic response in guiding decisions on individual-tailored treatments in cancer patients.

Risk Factors for Early Port Infections in Adult Oncologic Patients

2020 ◽  
Vol 31 (9) ◽  
pp. 1427-1436
Author(s):  
Philip Skummer ◽  
Katsuhiro Kobayashi ◽  
Joseph Sullivan DeRaddo ◽  
Taylor Blackburn ◽  
Mason Schoeneck ◽  
...  
Keyword(s):  
Risk Factors ◽  
Oncologic Patients

scholarly journals Optimization of contrast medium volume for abdominal CT in oncologic patients: prospective comparison between fixed and lean body weight-adapted dosing protocols

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Damiano Caruso ◽  
Elisa Rosati ◽  
Nicola Panvini ◽  
Marco Rengo ◽  
Davide Bellini ◽  
...  
Keyword(s):  
Body Weight ◽  
Image Quality ◽  
Contrast Media ◽  
Lower Amount ◽  
Fixed Dose ◽  
Lean Body Weight ◽  
Abdominal Ct ◽  
Oncologic Patients ◽  
Noise Ratio ◽  
Parenchymal Enhancement

Abstract Background Patient body size represents the main determinant of parenchymal enhancement and by adjusting the contrast media (CM) dose to patient weight may be a more appropriate approach to avoid a patient over dosage of CM. To compare the performance of fixed-dose and lean body weight (LBW)-adapted contrast media dosing protocols, in terms of image quality and parenchymal enhancement. Results One-hundred cancer patients undergoing multiphasic abdominal CT were prospectively enrolled in this multicentric study and randomly divided in two groups: patients in fixed-dose group (n = 50) received 120 mL of CM while in LBW group (n = 50) the amount of CM was computed according to the patient’s LBW. LBW protocol group received a significantly lower amount of CM (103.47 ± 17.65 mL vs. 120.00 ± 0.00 mL, p < 0.001). Arterial kidney signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) and pancreatic CNR were significantly higher in LBW group (all p ≤ 0.004). LBW group provided significantly higher arterial liver, kidney, and pancreatic contrast enhancement index (CEI) and portal venous phase kidney CEI (all p ≤ 0.002). Significantly lower portal vein SNR and CNR were observed in LBW-Group (all p ≤ 0.020). Conclusions LBW-adapted CM administration for abdominal CT reduces the volume of injected CM and improves both image quality and parenchymal enhancement.

scholarly journals A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: “Sapienza Head and Neck Unit” Proposal

2021 ◽  
Vol 18 (4) ◽  
pp. 1851
Author(s):  
Edoardo Brauner ◽  
Silvia Mezi ◽  
Alessandro Ciolfi ◽  
Chiara Ciolfi ◽  
Resi Pucci ◽  
...  
Keyword(s):  
Multidisciplinary Approach ◽  
Bone Cancer ◽  
Osteonecrosis Of The Jaw ◽  
Individual Risk ◽  
Medical Report ◽  
Oncologic Patients ◽  
Antiangiogenic Drugs ◽  
Dental Screening ◽  
The Individual

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse event associated with antiresorptive and antiangiogenic drugs. The use of these drugs in the treatment of cancer patients with bone metastasis is necessary and standardized in the literature. A multidisciplinary approach for the patient’s management is strongly recommended. Therefore, it should be necessary to integrate the path of these subjects with a dedicated dental screening in order to first assess the individual risk of developing a MRONJ, and then to plan dental treatments and oral hygiene sessions, and finally to schedule a follow-up to intercept and treat early osteonecrosis. The aim of this manuscript is to propose a new simple medical report to evaluate patients affected by metastatic bone cancer in order to reduce the risk of developing MRONJ.

scholarly journals Not all that glitters is COVID! Differential diagnosis of FDG-avid interstitial lung disease in low-prevalence regions

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Annalisa Papa ◽  
Chiara Pozzessere ◽  
Francesco Cicone ◽  
Fabiola Rizzuto ◽  
Giuseppe Lucio Cascini
Keyword(s):  
Differential Diagnosis ◽  
Interstitial Lung Diseases ◽  
Routine Activity ◽  
Imaging Features ◽  
Pet Ct ◽  
Oncologic Patients ◽  
The Many ◽  
Fdg Pet Ct ◽  
Low Prevalence ◽  
Similar Imaging

Abstract Coronavirus disease-19 (COVID-19) is only one of the many possible infectious and non-infectious diseases that may occur with similar imaging features in patients undergoing [18F]-fluorodeoxyglucose (18FDG) monitoring, particularly in the most fragile oncologic patients. We briefly summarise some key radiological elements of differential diagnosis of interstitial lung diseases which, in our opinion, could be extremely useful for physicians reporting 18FDG PET/CT scans, not only during the COVID-19 pandemic, but also for their normal routine activity.

scholarly journals What the Cardiologist Needs to Consider in the Management of Oncologic Patients with STEMI-Like Syndrome; A Case Report and Literature Review

2021 ◽  
Vol 14 (6) ◽  
pp. 563
Author(s):  
Aneta Aleksova ◽  
Giulia Gagno ◽  
Alessandro Pierri ◽  
Carla Todaro ◽  
Alessandra Lucia Fluca ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Case Report ◽  
Side Effects ◽  
Single Agent ◽  
St Segment Elevation ◽  
Cardiac Catheterization Laboratory ◽  
Cardiac Side Effects ◽  
Coronary Syndrome ◽  
St Segment ◽  
Oncologic Patients

In pre-hospital care, an accurate and quick diagnosis of ST-segment elevation myocardial infarction (STEMI) is imperative to promptly kick-off the STEMI network with a direct transfer to the cardiac catheterization laboratory (cath lab) in order to reduce myocardial infarction size and mortality. Aa atherosclerotic plaque rupture is the main mechanism responsible for STEMI. However, in a small percentage of patients, emergency coronarography does not reveal any significant coronary stenosis. The fluoropyrimidine agents such as 5-Fluorouracil (5-FU) and capecitabine, widely used to treat gastrointestinal, breast, head and neck cancers, either as a single agent or in combination with other chemotherapies, can cause potentially lethal cardiac side effects. Here, we present the case of a patient with 5-FU cardiotoxicity resulting in an acute coronary syndrome (ACS) with recurrent episodes of chest pain and ST-segment elevation.. Our case report highlights the importance of widening the knowledge among cardiologists of the side effects of chemotherapeutic drugs, especially considering the rising number of cancer patients around the world and that fluoropyrimidines are the main treatment for many types of cancer, both in adjuvant and advanced settings.

Sign in / Sign up

Export Citation Format

Share Document